Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis.

Autor: Alnor AB; Deptartment of Clinical Biochemistry, Odense University Hospital, Odense, Denmark. anne.alnor@rsyd.dk.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. anne.alnor@rsyd.dk., Gils C; Deptartment of Clinical Biochemistry, Odense University Hospital, Odense, Denmark., Vinholt PJ; Deptartment of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 Oct; Vol. 103 (10), pp. 4285-4294. Date of Electronic Publication: 2024 Aug 21.
DOI: 10.1007/s00277-024-05926-2
Abstrakt: This systematic review and meta-analysis assesses venous thromboembolism (VTE) risk in adults with hereditary thrombophilia, including Factor V Leiden (FVL) mutation, prothrombin G20210A (FII) mutation, compound heterozygosity, protein C (PC), protein S (PS), and antithrombin (AT) deficiency. Eligibility criteria included studies suitable for quantitative synthesis with extractable information on VTE risk in adults (> 15 years). There were no restrictions on VTE type, location, or occurrence. Two authors reviewed all studies and extracted data from 107 publications, encompassing 107,130 individuals (21,560 experiencing VTE). We used a random effects model and calculated odds ratios (ORs) with 95% confidence intervals (CIs). The highest risk was associated with homozygous FVL (OR 5.58, 95% CI 4.61-6.74), homozygous FII (OR 5.16, 95% CI 3.12-8.52), and compound heterozygosity (OR 4.64, 95% CI 2.25-9.58). In contrast, VTE risk was lowest for FVL heterozygosity (OR 2.97, 95% CI 2.41-3.67) and FII heterozygosity (OR 2.21, 95% CI 1.70-2.87), whereas PC (OR 3.23, 95% CI 2.05-5.08), PS (OR 3.01, 95% CI 2.26-4.02), and AT deficiency (OR 4.01, 95% CI 2.50-6.44) demonstrated an intermediate VTE risk. These results highlight an increased risk of venous thromboembolism in adults with hereditary thrombophilia. However, the risk for patients with PC, PS, and AT deficiency appears to be lower than previously stated, likely due to varying thrombogeneity of the underlying genetic mutations. Further research addressing this aspect of VTE risk in hereditary thrombophilia is imperative to improve patient management. TRIAL REGISTRATION: PROSPERO registration number CRD42022376757.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: